Pathology of Lung Cancer

Clinics in Chest Medicine

Volumn 32, Issue 4, 2011, Pages 669-692

  Travis, William D ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Lung cancer; Pathologic classification; Pathology

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR;

ADENOCARCINOMA IN SITU; ADENOSQUAMOUS CARCINOMA; ATYPICAL ADENOMATOUS HYPERPLASIA; BRONCHOSCOPY; CANCER CLASSIFICATION; CANCER SCREENING; CANCER STAGING; CARCINOID; CARCINOMA IN SITU; CARCINOSARCOMA; CLINICAL FEATURE; CYTODIAGNOSIS; DIFFERENTIAL DIAGNOSIS; DIFFUSE IDIOPATHIC PULMONARY NEUROENDOCRINE CELL HYPERPLASIA; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; LARGE CELL CARCINOMA; LUNG ADENOCARCINOMA; LUNG BIOPSY; LUNG BLASTOMA; LUNG CANCER; LUNG DISEASE; LUNG DYSPLASIA; LUNG NON SMALL CELL CANCER; LUNG RESECTION; LUNG SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MALIGNANT TRANSFORMATION; MEDICAL SOCIETY; MUTATIONAL ANALYSIS; NOMENCLATURE; PRECANCER; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SMALL CELL CARCINOMA; SPIRAL COMPUTER ASSISTED TOMOGRAPHY; TUMOR DIFFERENTIATION;

ADENOCARCINOMA; BIOPSY; CARCINOMA; CARCINOMA IN SITU; CARCINOMA, ADENOSQUAMOUS; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; HUMANS; LUNG; LUNG NEOPLASMS; SMALL CELL LUNG CARCINOMA;

EID: 80455123686     PISSN: 02725231     EISSN: 15578216     Source Type: Journal    
DOI: 10.1016/j.ccm.2011.08.005     Document Type: Review

References (163)

1. Jemal A., Bray F., Center M.M., et al. Global cancer statistics. CA Cancer J Clin 2011, 61:69-90.
2. Jemal A., Siegel R., Xu J., et al. Cancer statistics, 2010. CA Cancer J Clin 2010, 60:277-300.
3. Travis W.D., Lubin J., Ries L., et al. United States lung carcinoma incidence trends: declining for most histologic types among males, increasing among females. Cancer 1996, 77:2464-2470.
4. Rekhtman N., Brandt S.M., Sigel C.S., et al. Suitability of thoracic cytology for new therapeutic paradigms in non-small cell lung carcinoma: high accuracy of tumor subtyping and feasibility of EGFR and KRAS molecular testing. J Thorac Oncol 2011, 6:451-458.
5. Travis W.D., Brambilla E., Noguchi M., et al. The new IASLC/ATS/ERS international multidisciplinary lung adenocarcinoma classification. J Thorac Oncol 2011, 6:244-285.
6. Travis W.D., Brambilla E., Müller-Hermelink H.K., et al. Pathology and genetics: tumours of the lung, pleura, thymus and heart 2004, IARC, Lyon (France).
7. Travis W.D., Rekhtman N. Pathological diagnosis and classification of lung cancer in small biopsies and cytology: strategic management of tissue for molecular testing. Semin Respir Crit Care Med 2011, 32:22-31.
8. Nizzoli R., Tiseo M., Gelsomino F., et al. Accuracy of fine needle aspiration cytology in the pathological typing of non-small cell lung cancer. J Thorac Oncol 2011, 6:489-493.
9. Travis W.D., Brambilla E., Van Schil P., et al. Paradigm shifts in lung cancer as defined in the new IASLC/ATS/ERS lung adenocarcinoma classification. Eur Respir J 2011, 38:239-243.
10. Brambilla E., Gazdar A. Pathogenesis of lung cancer signalling pathways: roadmap for therapies. Eur Respir J 2009, 33:1485-1497.
11. Dacic S. Molecular diagnostics of lung carcinomas. Arch Pathol Lab Med 2011, 135:622-629.
12. Gomperts B.N., Spira A., Massion P.P., et al. Evolving concepts in lung carcinogenesis. Semin Respir Crit Care Med 2011, 32:32-43.
13. Dowell J., Minna J.D. Small-cell lung cancer: translational research enroute to therapeutic advances. Oncology (Williston Park) 2008, 22:1493-1495.
14. Travis W.D. Classification of lung cancer. Semin Roentgenol 2011, 46:178-186.
15. Wallace W.A. The challenge of classifying poorly differentiated tumours in the lung. Histopathology 2009, 54:28-42.
16. Idowu M.O., Powers C.N. Lung cancer cytology: potential pitfalls and mimics-a review. Int J Clin Exp Pathol 2010, 3:367-385.
17. Saad R.S., Silverman J.F. Respiratory cytology: differential diagnosis and pitfalls. Diagn Cytopathol 2010, 38:297-307.
18. Siddiqui M.T. Pulmonary neuroendocrine neoplasms: a review of clinicopathologic and cytologic features. Diagn Cytopathol 2010, 38:607-617.
19. Travis W.D., Rekhtman N., Riley G.J., et al. Pathologic diagnosis of advanced lung cancer based on small biopsies and cytology: a paradigm shift. J Thorac Oncol 2010, 5:411-414.
20. Mok T.S., Wu Y.L., Thongprasert S., et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009, 361:947-957.
21. Mitsudomi T., Morita S., Yatabe Y., et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 2010, 11:121-128.
22. Maemondo M., Inoue A., Kobayashi K., et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 2010, 362:2380-2388.
23. Zhou C., Wu Y.L., Chen G., et al. Efficacy results from the randomized phase III OPTIMAL (CTONG 0802) study comparing first-line erlotinib versus carboplatin (CBDCA) plus gemcitabine (GEM) in Chinese advanced non-small cell lung cancer (NSCLC) patients (PTS) with EGFR activating mutations. Ann Oncol 2010, 21:LBA13.
24. Rosell R., Gervais R., Vergnenegre A., et al. Erlotinib versus chemotherapy (CT) in advanced non-small cell lung cancer (NSCLC) patients (p) with epidermal growth factor receptor (EGFR) mutations: interim results of the European Erlotinib Versus Chemotherapy (EURTAC) phase III randomized trial. J Clin Oncol 2011, 29:7503. [abstract].
25. Ciuleanu T., Brodowicz T., Zielinski C., et al. Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study. Lancet 2009, 374:1432-1440.
26. Scagliotti G., Hanna N., Fossella F., et al. The differential efficacy of pemetrexed according to NSCLC histology: a review of two phase III studies. Oncologist 2009, 14:253-263.
27. Scagliotti G.V., Parikh P., von P.J., et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008, 26:3543-3551.
28. Scagliotti G., Brodowicz T., Shepherd F.A., et al. Treatment-by-histology interaction analyses in three phase III trials show superiority of pemetrexed in nonsquamous non-small cell lung cancer. J Thorac Oncol 2011, 6:64-70.
29. Johnson D.H., Fehrenbacher L., Novotny W.F., et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 2004, 22:2184-2191.
30. Ishizumi T., McWilliams A., MacAulay C., et al. Natural history of bronchial preinvasive lesions. Cancer Metastasis Rev 2010, 29:5-14.
31. Edell E., Lam S., Pass H., et al. Detection and localization of intraepithelial neoplasia and invasive carcinoma using fluorescence-reflectance bronchoscopy: an international, multicenter clinical trial. J Thorac Oncol 2009, 4:49-54.
32. Aberle D.R., Berg C.D., Black W.C., et al. The National Lung Screening Trial: overview and study design. Radiology 2011, 258:243-253.
33. Aberle D.R., Adams A.M., Berg C.D., et al. Baseline characteristics of participants in the Randomized National Lung Screening Trial. J Natl Cancer Inst 2010, 102:1771-1779.
34. Travis W.D. Lung. Pathology of incipient neoplasia 2001, 295-318. Oxford University Press, New York. 3rd edition. D.E. Henson, J. Albores-Saavedra (Eds.).
35. World Health Organization Histological typing of lung tumors 1981, World Health Organization, Geneva (Switzerland). 2nd edition.
36. Travis W.D., Colby T.V., Corrin B., et al. Histological Typing of Lung and Pleural Tumors 1999, In collaboration with L.H. Sobin and pathologists from 14 countries, Springer, Berlin. 3rd edition.
37. Travis W.D., Brambilla E. Pathology of lung preneoplasia. Textbook of prevention and detection of early lung cancer; International Association for the Study of Lung Cancer 2006, 75-89. Taylor & Francis, London and New York. 1st edition. F.R. Hirsch, P.A. Bunn, H. Kato (Eds.).
38. Lantuejoul S., Salameire D., Salon C., et al. Pulmonary preneoplasia-sequential molecular carcinogenetic events. Histopathology 2009, 54:43-54.
39. Nicholson A.G., Perry L.J., Cury P.M., et al. Reproducibility of the WHO/IASLC grading system for pre-invasive squamous lesions of the bronchus: a study of inter-observer and intra-observer variation. Histopathology 2001, 38:202-208.
40. Noguchi M. Stepwise progression of pulmonary adenocarcinoma-clinical and molecular implications. Cancer Metastasis Rev 2010, 29:15-21.
41. Yoo S.B., Chung J.H., Lee H.J., et al. Epidermal growth factor receptor mutation and p53 overexpression during the multistage progression of small adenocarcinoma of the lung. J Thorac Oncol 2010, 5:964-969.
42. Ruffini E., Bongiovanni M., Cavallo A., et al. The significance of associated pre-invasive lesions in patients resected for primary lung neoplasms. Eur J Cardiothorac Surg 2004, 26:165-172.
43. Kitamura H., Kameda Y., Ito T., et al. Atypical adenomatous hyperplasia of the lung. Implications for the pathogenesis of peripheral lung adenocarcinoma. Am J Clin Pathol 1999, 111:610-622.
44. Miller R.R. Bronchioloalveolar cell adenomas. Am J Surg Pathol 1990, 14:904-912.
45. Weng S.Y., Tsuchiya E., Kasuga T., et al. Incidence of atypical bronchioloalveolar cell hyperplasia of the lung: relation to histological subtypes of lung cancer. Virchows Arch A Pathol Anat Histopathol 1992, 420:463-471.
46. Carey F.A., Wallace W.A., Fergusson R.J., et al. Alveolar atypical hyperplasia in association with primary pulmonary adenocarcinoma: a clinicopathological study of 10 cases. Thorax 1992, 47:1041-1043.
47. Nakanishi K. Alveolar epithelial hyperplasia and adenocarcinoma of the lung. Arch Pathol Lab Med 1990, 114:363-368.
48. Mori M., Chiba R., Tezuka F., et al. Papillary adenoma of type II pneumocytes might have malignant potential. Virchows Arch 1996, 428:195-200.
49. Mori M., Chiba R., Takahashi T. Atypical adenomatous hyperplasia of the lung and its differentiation from adenocarcinoma. Characterization of atypical cells by morphometry and multivariate cluster analysis. Cancer 1993, 72:2331-2340.
50. Ritter J.H. Pulmonary atypical adenomatous hyperplasia. A histologic lesion in search of usable criteria and clinical significance. Am J Clin Pathol 1999, 111:587-589.
51. Suzuki K., Nagai K., Yoshida J., et al. The prognosis of resected lung carcinoma associated with atypical adenomatous hyperplasia: a comparison of the prognosis of well-differentiated adenocarcinoma associated with atypical adenomatous hyperplasia and intrapulmonary metastasis. Cancer 1997, 79:1521-1526.
52. Watanabe S., Watanabe T., Arai K., et al. Results of wedge resection for focal bronchioloalveolar carcinoma showing pure ground-glass attenuation on computed tomography. Ann Thorac Surg 2002, 73:1071-1075.
53. Sakurai H., Dobashi Y., Mizutani E., et al. Bronchioloalveolar carcinoma of the lung 3 centimeters or less in diameter: a prognostic assessment. Ann Thorac Surg 2004, 78:1728-1733.
54. Vazquez M., Carter D., Brambilla E., et al. Solitary and multiple resected adenocarcinomas after CT screening for lung cancer: histopathologic features and their prognostic implications. Lung Cancer 2009, 64:148-154.
55. Yamato Y., Tsuchida M., Watanabe T., et al. Early results of a prospective study of limited resection for bronchioloalveolar adenocarcinoma of the lung. Ann Thorac Surg 2001, 71:971-974.
56. Yoshida J., Nagai K., Yokose T., et al. Limited resection trial for pulmonary ground-glass opacity nodules: fifty-case experience. J Thorac Cardiovasc Surg 2005, 129:991-996.
57. Koike T., Togashi K., Shirato T., et al. Limited resection for noninvasive bronchioloalveolar carcinoma diagnosed by intraoperative pathologic examination. Ann Thorac Surg 2009, 88:1106-1111.
58. Noguchi M., Morikawa A., Kawasaki M., et al. Small adenocarcinoma of the lung. Histologic characteristics and prognosis. Cancer 1995, 75:2844-2852.
59. Yim J., Zhu L.C., Chiriboga L., et al. Histologic features are important prognostic indicators in early stages lung adenocarcinomas. Mod Pathol 2007, 20:233-241.
60. Aguayo S.M., Miller Y.E., Waldron J.A., et al. Brief report: idiopathic diffuse hyperplasia of pulmonary neuroendocrine cells and airways disease. N Engl J Med 1992, 327:1285-1288.
61. Davies S.J., Gosney J.R., Hansell D.M., et al. Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia: an under-recognised spectrum of disease. Thorax 2007, 62:248-252.
62. Koo C.W., Baliff J.P., Torigian D.A., et al. Spectrum of pulmonary neuroendocrine cell proliferation: diffuse idiopathic pulmonary neuroendocrine cell hyperplasia, tumorlet, and carcinoids. AJR Am J Roentgenol 2010, 195:661-668.
63. Travis W.D., Travis L.B., Devesa S.S. Lung cancer. Cancer 1995, 75:191-202. [Published erratum appears in Cancer 1995 Jun 15;75(12):2979].
64. Tomashefski J.F., Connors A.F., Rosenthal E.S., et al. Peripheral vs central squamous cell carcinoma of the lung. A comparison of clinical features, histopathology, and survival. Arch Pathol Lab Med 1990, 114:468-474.
65. Colby T.V., Koss M.N., Travis W.D. Tumors of the lower respiratory tract; Armed Forces Institute of Pathology fascicle, third series 1995, Armed Forces Institute of Pathology, Washington, DC.
66. Funai K., Yokose T., Ishii G., et al. Clinicopathologic characteristics of peripheral squamous cell carcinoma of the lung. Am J Surg Pathol 2003, 27:978-984.
67. Carlile A., Edwards C. Poorly differentiated squamous carcinoma of the bronchus: a light and electron microscopic study. J Clin Pathol 1986, 39:284-292.
68. Melamed M.R., Zaman M.B., Flehinger B.J., et al. Radiologically occult in situ and incipient invasive epidermoid lung cancer: detection by sputum cytology in a survey of asymptomatic cigarette smokers. Am J Surg Pathol 1977, 1:5-16.
69. Churg A., Johnston W.H., Stulbarg M. Small cell squamous and mixed small cell squamous-small cell anaplastic carcinomas of the lung. Am J Surg Pathol 1980, 4:255-263.
70. Dulmet-Brender E., Jaubert F., Huchon G. Exophytic endobronchial epidermoid carcinoma. Cancer 1986, 57:1358-1364.
71. Sherwin R.P., Laforet E.G., Strieder J.W. Exophytic endobronchial carcinoma. J Thorac Cardiovasc Surg 1962, 43:716-730.
72. Maeshima A.M., Maeshima A., Asamura H., et al. Histologic prognostic factors for small-sized squamous cell carcinomas of the peripheral lung. Lung Cancer 2006, 52:53-58.
73. Watanabe Y., Yokose T., Sakuma Y., et al. Alveolar space filling ratio as a favorable prognostic factor in small peripheral squamous cell carcinoma of the lung. Lung Cancer 2011, 73(2):217-221.
74. Yousem S.A. Peripheral squamous cell carcinoma of lung: patterns of growth with particular focus on airspace filling. Hum Pathol 2009, 40:861-867.
75. Altekruse S.F., Kosary C.L., Krapcho M., et al. SEER cancer statistics review, 1975-2007 2010, National Cancer Institute, Available at:, Accessed December 12, 2010. http://seer.cancer.gov/csr/1975_2007/.
76. Yoshizawa A., Motoi N., Riely G.J., et al. Impact of proposed IASLC/ATS/ERS classification of lung adenocarcinoma: prognostic subgroups and implications for further revision of staging based on analysis of 514 stage I cases. Mod Pathol 2011, 24:653-664.
77. Borczuk A.C., Qian F., Kazeros A., et al. Invasive size is an independent predictor of survival in pulmonary adenocarcinoma. Am J Surg Pathol 2009, 33:462-469.
78. Suzuki K., Yokose T., Yoshida J., et al. Prognostic significance of the size of central fibrosis in peripheral adenocarcinoma of the lung. Ann Thorac Surg 2000, 69:893-897.
79. Miyoshi T., Satoh Y., Okumura S., et al. Early-stage lung adenocarcinomas with a micropapillary pattern, a distinct pathologic marker for a significantly poor prognosis. Am J Surg Pathol 2003, 27:101-109.
80. Tsutsumida H., Nomoto M., Goto M., et al. A micropapillary pattern is predictive of a poor prognosis in lung adenocarcinoma, and reduced surfactant apoprotein A expression in the micropapillary pattern is an excellent indicator of a poor prognosis. Mod Pathol 2007, 20:638-647.
81. Cohen P.R., Yoshizawa A., Motoi N., et al. Signet ring cell features (SRCF) in lung adenocarcinoma: a cytologic feature or a histologic subtype?. Mod Pathol 2010, 23:400A.
82. Deshpande C.G., Yoshizawa A., Motoi N., et al. Clear cell change in lung adenocarcinoma: a cytologic change rather than a histologic variant. Mod Pathol 2009, 22:352A.
83. Sakurai H., Maeshima A., Watanabe S., et al. Grade of stromal invasion in small adenocarcinoma of the lung: histopathological minimal invasion and prognosis. Am J Surg Pathol 2004, 28:198-206.
84. Kadota K, Suzuki K, D'Angelo SP, et al. Validation of the proposed IASLC/American Thoracic Society (ATS)/European Respiratory Society (ERS) international multidisciplinary classification of lung adenocarcinoma (ADC). J Thorac Oncol 2011;6:244-85.
85. Yoshizawa A., Sumiyoshi S., Moreira A.L., et al. Validation of the IASLC/ATS/ERS lung adenocarcinoma (ADC) classification and use of comprehensive histologic subtyping (CHS) for architectural grading in 432 Japanese patients. Mod Pathol 2011, 24:429A.
86. Girard N., Deshpande C., Azzoli C.G., et al. Use of epidermal growth factor receptor/Kirsten rat sarcoma 2 viral oncogene homolog mutation testing to define clonal relationships among multiple lung adenocarcinomas: comparison with clinical guidelines. Chest 2010, 137:46-52.
87. Girard N., Deshpande C., Lau C., et al. Comprehensive histologic assessment helps to differentiate multiple lung primary nonsmall cell carcinomas from metastases. Am J Surg Pathol 2009, 33:1752-1764.
88. Girard N., Ostrovnaya I., Lau C., et al. Genomic and mutational profiling to assess clonal relationships between multiple non-small cell lung cancers. Clin Cancer Res 2009, 15:5184-5190.
89. Ou S.H., Zell J.A. Carcinoma NOS is a common histologic diagnosis and is increasing in proportion among non-small cell lung cancer histologies. J Thorac Oncol 2009, 4:1202-1211.
90. Solomon S.B., Zakowski M.F., Pao W., et al. Core needle lung biopsy specimens: adequacy for EGFR and KRAS mutational analysis. AJR Am J Roentgenol 2010, 194:266-269.
91. Kreisman H., Wolkove N., Quoix E. Small cell lung cancer presenting as a solitary pulmonary nodule. Chest 1992, 101:225-231.
92. Gephardt G.N., Grady K.J., Ahmad M., et al. Peripheral small cell undifferentiated carcinoma of the lung. Clinicopathologic features of 17 cases. Cancer 1988, 61:1002-1008.
93. Hirsch F.R., Matthews M.J., Aisner S., et al. Histopathologic classification of small cell lung cancer. Changing concepts and terminology. Cancer 1988, 62:973-977.
94. Fraire A.E., Johnson E.H., Yesner R., et al. Prognostic significance of histopathologic subtype and stage in small cell lung cancer. Hum Pathol 1992, 23:520-528.
95. Nicholson S.A., Beasley M.B., Brambilla E., et al. Small cell lung carcinoma (SCLC): a clinicopathologic study of 100 cases with surgical specimens. Am J Surg Pathol 2002, 26:1184-1197.
96. Travis W.D. Advances in neuroendocrine lung tumors. Ann Oncol 2010, 21(Suppl 7):vii65-vii71.
97. Azzopardi J.G. Oat-cell carcinoma of the bronchus. J Pathol Bacteriol 1959, 78:513-519.
98. Bégin P., Sahai S., Wang N.S. Giant cell formation in small cell carcinoma of the lung. Cancer 1983, 52:1875-1879.
99. Sehested M., Hirsch F.R., Osterlind K., et al. Morphologic variations of small cell lung cancer. A histopathologic study of pretreatment and posttreatment specimens in 104 patients. Cancer 1986, 57:804-807.
100. Bepler G., Neumann K., Holle R., et al. Clinical relevance of histologic subtyping in small cell lung cancer. Cancer 1989, 64:74-79.
101. Mangum M.D., Greco F.A., Hainsworth J.D., et al. Combined small-cell and non-small-cell lung cancer. J Clin Oncol 1989, 7:607-612.
102. Tsubota Y.T., Kawaguchi T., Hoso T., et al. A combined small cell and spindle cell carcinoma of the lung. Report of a unique case with immunohistochemical and ultrastructural studies. Am J Surg Pathol 1992, 16:1108-1115.
103. Fishback N.F., Travis W.D., Moran C.A., et al. Pleomorphic (spindle/giant cell) carcinoma of the lung. A clinicopathologic correlation of 78 cases. Cancer 1994, 73:2936-2945.
104. Sümmermann E., Huwer H., Seitz G. Carcinosarcoma of the lung, a tumour which has a poor prognosis and is extremely rarely diagnosed preoperatively. Thorac Cardiovasc Surg 1990, 38:247-250.
105. Folpe A.L., Gown A.M., Lamps L.W., et al. Thyroid transcription factor-1: immunohistochemical evaluation in pulmonary neuroendocrine tumors. Mod Pathol 1999, 12:5-8.
106. Sturm N., Rossi G., Lantuejoul S., et al. Expression of thyroid transcription factor-1 in the spectrum of neuroendocrine cell lung proliferations with special interest in carcinoids. Hum Pathol 2002, 33:175-182.
107. Sturm N., Lantuejoul S., Laverriere M.H., et al. Thyroid transcription factor 1 and cytokeratins 1, 5, 10, 14 (34betaE12) expression in basaloid and large-cell neuroendocrine carcinomas of the lung. Hum Pathol 2001, 32:918-925.
108. Travis W.D. Neuroendocrine lung tumors. Path Case Rev 2006, 11:235-242.
109. Travis W.D. Lung tumours with neuroendocrine differentiation. Eur J Cancer 2009, 45(Suppl 1):251-266.
110. Agoff S.N., Lamps L.W., Philip A.T., et al. Thyroid transcription factor-1 is expressed in extrapulmonary small cell carcinomas but not in other extrapulmonary neuroendocrine tumors. Mod Pathol 2000, 13:238-242.
111. Pelosi G., Rodriguez J., Viale G., et al. Typical and atypical pulmonary carcinoid tumor overdiagnosed as small-cell carcinoma on biopsy specimens: a major pitfall in the management of lung cancer patients. Am J Surg Pathol 2005, 29:179-187.
112. Krug L.M., Pietanza M.C., Kris M.G., et al. Small cell and other neuroendocrine tumors of the lung. DeVita, Hellman and Rosenberg's cancer, principles and practice of oncology 2011, 848-870. Wolters Kluwer; Lippincott Williams & Wilkins, Philadelphia. 9th edition. V.T. DeVita, T.S. Lawrence, S.A. Rosenberg (Eds.).
113. Vollmer R.T. The effect of cell size on the pathologic diagnosis of small and large cell carcinomas of the lung. Cancer 1982, 50:1380-1383.
114. Vollmer R.T., Ogden L., Crissman J.D. Separation of small-cell from non-small-cell lung cancer. The Southeastern Cancer Study Group pathologists' experience. Arch Pathol Lab Med 1984, 108:792-794.
115. Roggli V.L., Vollmer R.T., Greenberg S.D., et al. Lung cancer heterogeneity: a blinded and randomized study of 100 consecutive cases. Hum Pathol 1985, 16:569-579.
116. Travis W.D., Gal A.A., Colby T.V., et al. Reproducibility of neuroendocrine lung tumor classification. Hum Pathol 1998, 29:272-279.
117. Marchevsky A.M., Chuang M.T., Teirstein A.S., et al. Problems in the diagnosis of small cell carcinoma of the lungs by fiberoptic bronchoscopy. Cancer Detect Prev 1984, 7:253-260.
118. Travis W.D., Garg K., Franklin W.A., et al. Bronchioloalveolar carcinoma and lung adenocarcinoma: the clinical importance and research relevance of the 2004 World Health Organization pathologic criteria. J Thorac Oncol 2006, 1:S13-S19.
119. Hiroshima K., Iyoda A., Shida T., et al. Distinction of pulmonary large cell neuroendocrine carcinoma from small cell lung carcinoma: a morphological, immunohistochemical, and molecular analysis. Mod Pathol 2006, 19:1358-1368.
120. Souhami R.L., Beverley P.C., Bobrow L.G. Antigens of small-cell lung cancer. First International Workshop. Lancet 1987, 2:325-326.
121. Tome Y., Hirohashi S., Noguchi M., et al. Preservation of cluster 1 small cell lung cancer antigen in zinc-formalin fixative and its application to immunohistological diagnosis. Histopathology 1990, 16:469-474.
122. Maleki Z. Diagnostic issues with cytopathologic interpretation of lung neoplasms displaying high-grade basaloid or neuroendocrine morphology. Diagn Cytopathol 2011, 39:159-167.
123. Sun Z., Aubry M.C., Deschamps C., et al. Histologic grade is an independent prognostic factor for survival in non-small cell lung cancer: an analysis of 5018 hospital- and 712 population-based cases. J Thorac Cardiovasc Surg 2006, 131:1014-1020.
124. Sawabata N., Asamura H., Goya T., et al. Japanese Lung Cancer Registry Study: first prospective enrollment of a large number of surgical and nonsurgical cases in 2002. J Thorac Oncol 2010, 5:1369-1375.
125. Rossi G., Marchioni A., Milani M., et al. TTF-1, cytokeratin 7, 34betaE12, and CD56/NCAM immunostaining in the subclassification of large cell carcinomas of the lung. Am J Clin Pathol 2004, 122:884-893.
126. Churg A. The fine structure of large cell undifferentiated carcinoma of the lung. Evidence for its relation to squamous cell carcinomas and adenocarcinomas. Hum Pathol 1978, 9:143-156.
127. Horie A., Ohta M. Ultrastructural features of large cell carcinoma of the lung with reference to the prognosis of patients. Hum Pathol 1981, 12:423-432.
128. Kodama T., Shimosato Y., Koide T., et al. Large cell carcinoma of the lung-ultrastructural and immunohistochemical studies. Jpn J Clin Oncol 1985, 15:431-441.
129. Carvalho L. Reclassifying bronchial-pulmonary carcinoma: differentiating histological type in biopsies by immunohistochemistry. Rev Port Pneumol 2009, 15:1101-1119.
130. Travis W.D., Rush W., Flieder D.B., et al. Survival analysis of 200 pulmonary neuroendocrine tumors with clarification of criteria for atypical carcinoid and its separation from typical carcinoid. Am J Surg Pathol 1998, 22:934-944.
131. Travis W.D., Linnoila R.I., Tsokos M.G., et al. Neuroendocrine tumors of the lung with proposed criteria for large-cell neuroendocrine carcinoma. An ultrastructural, immunohistochemical, and flow cytometric study of 35 cases. Am J Surg Pathol 1991, 15:529-553.
132. Moro-Sibilot D., Lantuejoul S., Diab S., et al. Lung carcinomas with a basaloid pattern: a study of 90 cases focusing on their poor prognosis. Eur Respir J 2008, 31:854-859.
133. Chang Y.L., Wu C.T., Shih J.Y., et al. Unique p53 and epidermal growth factor receptor gene mutation status in 46 pulmonary lymphoepithelioma-like carcinomas. Cancer Sci 2011, 102:282-287.
134. Chang Y.L., Wu C.T., Shih J.Y., et al. New aspects in clinicopathologic and oncogene studies of 23 pulmonary lymphoepithelioma-like carcinomas. Am J Surg Pathol 2002, 26:715-723.
135. Katzenstein A.L., Prioleau P.G., Askin F.B. The histologic spectrum and significance of clear-cell change in lung carcinoma. Cancer 1980, 45:943-947.
136. Cavazza A., Colby T.V., Tsokos M., et al. Lung tumors with a rhabdoid phenotype. Am J Clin Pathol 1996, 105:182-188.
137. Izquierdo-Garcia F.M., Moreno-Mata N., Herranz-Aladro M.L., et al. Lung carcinoma with rhabdoid component. A series of seven cases associated with uncommon types of non-small cell lung carcinomas and alveolar entrapment. Histol Histopathol 2010, 25:1287-1295.
138. Wiatrowska B.A., Krol J., Zakowski M.F. Large-cell neuroendocrine carcinoma of the lung: proposed criteria for cytologic diagnosis. Diagn Cytopathol 2001, 24:58-64.
139. Iyoda A., Hiroshima K., Toyozaki T., et al. Clinical characterization of pulmonary large cell neuroendocrine carcinoma and large cell carcinoma with neuroendocrine morphology. Cancer 2001, 91:1992-2000.
140. Jiang S.X., Kameya T., Shoji M., et al. Large cell neuroendocrine carcinoma of the lung: a histologic and immunohistochemical study of 22 cases. Am J Surg Pathol 1998, 22:526-537.
141. Beasley M.B., Thunnissen F.B., Brambilla E., et al. Pulmonary atypical carcinoid: predictors of survival in 106 cases. Hum Pathol 2000, 31:1255-1265.
142. Varlotto J.M., Medford-Davis L.N., Recht A., et al. Should large cell neuroendocrine lung carcinoma be classified and treated as a small cell lung cancer or with other large cell carcinomas?. J Thorac Oncol 2011, 6:1050-1058.
143. Graziano S.L., Mazid R., Newman N., et al. The use of neuroendocrine immunoperoxidase markers to predict chemotherapy response in patients with non-small-cell lung cancer. J Clin Oncol 1989, 7:1398-1406.
144. Gazdar A.F., Kadoyama C., Venzon D., et al. Association between histological type and neuroendocrine differentiation on drug sensitivity of lung cancer cell lines. J Natl Cancer Inst Monogr 1992, 13:191-196.
145. Berendsen H.H., de Leij L., Poppema S., et al. Clinical characterization of non-small-cell lung cancer tumors showing neuroendocrine differentiation features. J Clin Oncol 1989, 7:1614-1620.
146. Kibbelaar R.E., Moolenaar K.E., Michalides R.J., et al. Neural cell adhesion molecule expression, neuroendocrine differentiation and prognosis in lung carcinoma. Eur J Cancer 1991, 27:431-435.
147. Schleusener J.T., Tazelaar H.D., Jung S.H., et al. Neuroendocrine differentiation is an independent prognostic factor in chemotherapy-treated nonsmall cell lung carcinoma. Cancer 1996, 77:1284-1291.
148. Addis B.J. Neuroendocrine differentiation in lung carcinoma. Thorax 1995, 50:113-115. [editorial].
149. Kiriakogiani-Psaropoulou P., Malamou-Mitsi V., Martinopoulou U., et al. The value of neuroendocrine markers in non-small cell lung cancer: a comparative immunohistopathologic study. Lung Cancer 1994, 11:353-364.
150. Linnoila R.I., Piantadosi S., Ruckdeschel J.C. Impact of neuroendocrine differentiation in non-small cell lung cancer. The LCSG experience. Chest 1994, 106:367S-371S.
151. Carles J., Rosell R., Ariza A., et al. Neuroendocrine differentiation as a prognostic factor in non-small cell lung cancer. Lung Cancer 1993, 10:209-219.
152. Skov B.G., Sorensen J.B., Hirsch F.R., et al. Prognostic impact of histologic demonstration of chromogranin A and neuron specific enolase in pulmonary adenocarcinoma. Ann Oncol 1991, 2:355-360.
153. Fitzgibbons P.L., Kern W.H. Adenosquamous carcinoma of the lung: a clinical and pathologic study of seven cases. Hum Pathol 1985, 16:463-466.
154. Ishida T., Kaneko S., Yokoyama H., et al. Adenosquamous carcinoma of the lung. Clinicopathologic and immunohistochemical features. Am J Clin Pathol 1992, 97:678-685.
155. Naunheim K.S., Taylor J.R., Skosey C., et al. Adenosquamous lung carcinoma: clinical characteristics, treatment, and prognosis. Ann Thorac Surg 1987, 44:462-466.
156. Sridhar K.S., Raub W.A., Duncan R.C., et al. The increasing recognition of adenosquamous lung carcinoma (1977-1986). Am J Clin Oncol 1992, 15:356-362.
157. Takamori S., Noguchi M., Morinaga S., et al. Clinicopathologic characteristics of adenosquamous carcinoma of the lung. Cancer 1991, 67:649-654.
158. Travis W.D. Sarcomatoid neoplasms of the lung and pleura. Arch Pathol Lab Med 2010, 134:1645-1658.
159. Asamura H., Kameya T., Matsuno Y., et al. Neuroendocrine neoplasms of the lung: a prognostic spectrum. J Clin Oncol 2006, 24:70-76.
160. Lack E.E., Harris G.B., Eraklis A.J., et al. Primary bronchial tumors in childhood. A clinicopathologic study of six cases. Cancer 1983, 51:492-497.
161. Naalsund A., Rostad H., Strom E.H., et al. Carcinoid lung tumors-incidence, treatment and outcomes: a population-based study. Eur J Cardiothorac Surg 2011, 39:565-569.
162. Rea F., Rizzardi G., Zuin A., et al. Outcome and surgical strategy in bronchial carcinoid tumors: single institution experience with 252 patients. Eur J Cardiothorac Surg 2007, 31:186-191.
163. Iyoda A., Hiroshima K., Moriya Y., et al. Pulmonary large cell neuroendocrine carcinoma demonstrates high proliferative activity. Ann Thorac Surg 2004, 77:1891-1895.